|
Multaq Sanctioned for Heart Rhythm Disorders
Atrial fibrillation or atrial flutter
Thu Jul 02, 2009, 10:58
|
Story Tools
|
|
•
|
Printable
version
|
|
•
|
Jul 02, 2009 News
|
|
Related News Categories
| | • | Heart / Stroke-Related: Misc | | • | Food & Drug Administration | | • | Drug Approvals |
Related News
| • | Cholesterol Plays Role in Heart Failure Risk - Nov 24, 2009 | • | Smokers Double Their Risk for Heart Disease - Nov 24, 2009 | • | Vioxx Problems Known Years Before Recall - Nov 23, 2009 | • | Vigorous Exercise Cuts Stroke Risk for Men, Not Women - Nov 23, 2009 | • | Diet, Cognitive Ability May Play Role in Heart Disease - Nov 19, 2009 | • | For Chest Pain in the ER, CT Angiography May Be Best - Nov 19, 2009 | • | Diuretics Still Best Treatment for High Blood Pressure - Nov 18, 2009 | • | Study Shows Hospital Report Cards Unlikely to Spur Improvement - Nov 18, 2009 | • | Niacin Adds No Benefit for Statin Patients: Study - Nov 18, 2009 | • | Lifelong Exercise Keeps Seniors Young at Heart - Nov 18, 2009 | • | Toddlers, Obese Kids Suffer Most From Smoke - Nov 18, 2009 | • | Heartburn Drugs Can Thwart Popular Blood Thinner - Nov 17, 2009 | • | Qutenza Approved for Post-Shingles Nerve Pain - Nov 17, 2009 | • | Benefits of Eating Fish May Depend on Preparation - Nov 17, 2009 | • | Heart Failure Drug May Help More in Higher Doses - Nov 18, 2009 |
THURSDAY, July 2 (HealthDay News) -- Multaq (dronedarone) tablets have been approved by the U.S. Food and Drug Administration to promote a normal heart rhythm in people with atrial fibrillation or atrial flutter. These conditions cause the heart to beat too quickly and can prevent it from pumping blood correctly.
The drug's label, however, will contain a "black box" warning that the medication could cause deadly reactions in people with recent severe heart failure, the agency said Thursday in a news release.
In clinical testing involving more than 4,000 people, Multaq lowered the rates of cardiac hospitalization or death from any cause by 24 percent, compared to an inactive placebo, the FDA said. The most common side effects were diarrhea, nausea, vomiting, fatigue and weakness.
Multaq is produced by French drug maker Sanofi-Aventis.
More information
The FDA has more about this approval.
Copyright © 2009 ScoutNews, LLC. All rights reserved.
Today's Top News Stories | • | Ginkgo Won't Prevent Heart Attack, Stroke in Elderly - Nov 24, 2009, 16:00
But the herbal supplement may help ward off peripheral artery disease, researchers say. | • | Dangerous Toys Still on Store Shelves, Report Finds - Nov 24, 2009, 16:00
Focus on toys that pose choking hazard, are too loud, or contain dangerous chemicals. | • | Chronic Pain Trips Up Seniors - Nov 24, 2009, 16:00
Discomfort contributes to the falls that plague older adults, study finds. | • | Clinical Trials Update: Nov. 24, 2009 - Nov 24, 2009, 11:14
- Constipation
- Healthy Volunteers (Ages 18-65)
- Type 2 Diabetes
| • | Angioplasty Outcomes May Vary Little Between Hospitals - Nov 24, 2009, 16:00
In-hospital death rates didn't differ greatly between high- and low-volume centers, study found. |
|
|
|
